USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
TARGESON, LLC
Address:
850 CARLINS WAY
CHARLOTTESVILLE, VA 22903-7666
Phone:
N/A
URL:
N/A
EIN:
127006058
DUNS:
610945474
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $843,709.00 6
SBIR Phase II $1,030,154.00 1

Award List:

Gene Delivery Agents for Ultrasound-Mediated Transfection

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$99,867.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): We propose to develop a novel acoustically activated microbubble gene delivery vehicle for treatment of experimental inflammatory bowel disease. Microbubble ultrasound contrast agents composed of a cationic lipid shell are targeted to the adhesion molecule… More

Multi-Targeted Contrast Ultrasound Agent for Imaging Angiogenesis

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$104,679.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Targeson has developed and commercialized a microbubble contrast agent that is suitable for conjugation to an array of molecular targeting ligands via an avidin/biotin coupling system. The potential immunogenicity and t oxicity of the avidin/biotin system, as… More

Ultrasound Contrast Agents for Inflammation and Angiogenesis

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$99,729.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): We propose to develop molecular imaging probes for imaging angiogenesis and inflammation using contrast-enhanced ultrasound. These probes are gas-encapsulated microbubbles that can be coated with ligands specific for mo lecular markers of disease using robust… More

Ultrasound mediated targeted therapy for kidney disease

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$166,046.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Antibodies can be used diagnostically as ligands for molecular imaging, and also as therapeutic to neutralize factors involved in the development of kidney disease. However, the systemic administration of many relevant antibodies may lead to serious side-effects… More

Ultrasound Contrast Agents for Inflammation and Angiogenesis

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$1,030,154.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Site-targeted microbubbles (MB) have demonstrated potential as a molecular imaging tool. A new targeted MB platform was developed in phase I of this project. This MB enables covalent coupling of targeting ligands using thioether conjugation chemistry. MB bearing… More

Novel Microparticle Contrast Agent for Near Infrared Molecular Imaging

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$177,726.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Molecular imaging techniques have demonstrated efficacy in the setting of preclinical research, primarily for drug discovery and basic science. Optical imaging has emerged as a market leader in the field, owing to the a vailability of easy-to-use contrast agents… More

Contrast agents for high-sensitivity ultrasound molecular imaging of tumor angiog

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$195,662.00
Agency:
HHS
Principal Investigator:
Joshua J. Rychak – 877-290-4043
Abstract:
DESCRIPTION (provided by applicant): Molecular imaging techniques have strong potential in the setting of preclinical research, primarily for drug discovery and basic science in the field of cancer research. In particular, high-frequency ultrasound is a powerful imaging modality for phenotyping and… More